13G Filing: Partner Fund Management and Portola Pharmaceuticals Inc (PTLA)

Page 2 of 13

Page 2 of 13 – SEC Filing

CUSIP
No.
737010108
13G Page
2 of 13 Pages

1.

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Partner Fund Management, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)      ¨

(b)     x

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

 

3,230,997 shares

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.7%1

12.

TYPE OF REPORTING PERSON

IA; PN

1 The percentages reported in this Schedule 13G are based upon 57,020,110 shares of common stock outstanding as of May 3, 2017
according Form 10-Q filed by the issuer with the Securities and Exchange Commission on May 9, 2017. All of the other numbers
and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing.

Follow Portola Pharmaceuticals Inc (NASDAQ:PTLA)





Page 2 of 13